Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12).

Authors: Arnoud J. Templeton, Stefanie Hayoz, Simone Wyss-Neyer, Richard Cathomas, Ricardo Pereira Mestre, Christian Alexander Rothermundt, Sandro Anchisi, Christoph Jakob Ackermann, Katharina Reichel, Beat Mueller, Claudine Egger, Augusto Pedrazzini, Razvan Andrei Popescu, Lena Züllig, Regina Woelky, Priska Bützberger, Florian Schmid, Roger Anton Fredy Von Moos, Silke Gillessen

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.163

Source: Full article

---

Abstract

163